12:00 AM
 | 
Jul 29, 2002
 |  BioCentury  |  Product Development

Sitaxsentan: Waiting for efficacy

It's too early to jump to conclusions about the meaning of the liver abnormalities seen in trials of sitaxsentan, an endothelin receptor antagonist being developed by Texas Biotechnology Corp. and partner Icos Corp. to treat pulmonary arterial hypertension (PAH). The side effect appears to be endemic to this class of compounds, and the real decision will come in the fourth quarter when the companies have efficacy data that will enable them to weigh the risk-benefit of the molecule.

TXBI (Houston, Texas) and ICOS (Bothell, Wash.) last week ended an extension study of their Phase IIb/III STRIDE trial of sitaxsentan for ethical reasons. The trial, which has completed enrollment of...

Read the full 538 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >